These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 23919486

  • 1. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
    Giral M, Foucher Y, Dufay A, Duong Van Huyen JP, Renaudin K, Moreau A, Philippe A, Hegner B, Dechend R, Heidecke H, Brouard S, Cesbron A, Castagnet S, Devys A, Soulillou JP, Dragun D.
    Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
    Malheiro J, Tafulo S, Dias L, Martins S, Fonseca I, Beirão I, Castro-Henriques A, Cabrita A.
    Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
    Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Loupy A, Halloran PF, Dragun D.
    Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E, Arreola-Guerra JM, Hernández-Méndez EA, Salcedo I, Castelán N, Uribe-Uribe NO, Vilatobá M, Contreras-Saldívar AG, Sánchez-Cedillo AI, Ramírez JB, de Rungs D, Granados J, Morales-Buenrostro LE, Alberú J.
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [Abstract] [Full Text] [Related]

  • 10. ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts.
    Betjes MGH, Sablik KA, Litjens NHR, Otten HG, de Weerd AE.
    Hum Immunol; 2021 Feb; 82(2):89-96. PubMed ID: 33358038
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
    El Band JEK, Llorente S, Martinez-Garcia P, Alfaro R, Jimenez-Coll V, Boix F, Galián JA, Martinez-Banaclocha H, Botella C, Moya-Quiles MR, Minguela A, Legaz I, Muro M.
    Curr Protein Pept Sci; 2021 Feb; 22(10):745-757. PubMed ID: 34967284
    [Abstract] [Full Text] [Related]

  • 12. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.
    Lee J, Park Y, Kim BS, Lee JG, Kim HJ, Kim YS, Huh KH.
    Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704
    [Abstract] [Full Text] [Related]

  • 13. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
    Philogene MC, Bagnasco S, Kraus ES, Montgomery RA, Dragun D, Leffell MS, Zachary AA, Jackson AM.
    Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of angiotensin II type 1 receptor antibodies on graft function and survival in paediatric kidney transplant recipients.
    Kermond RF, Kim S, Mackie F, Hahn D, Carroll RP, Sharma A, Durkan AM.
    HLA; 2024 Sep; 104(3):e15649. PubMed ID: 39247998
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of anti-angiotensin II type 1 receptor antibodies on the outcomes of kidney transplantation: a systematic review and meta-analysis.
    Kang ZY, Liu C, Liu W, Li DH.
    Nephrol Dial Transplant; 2022 May 25; 37(6):1171-1180. PubMed ID: 34865146
    [Abstract] [Full Text] [Related]

  • 18. Pre-transplant AT1R antibodies and long-term outcomes in kidney transplant recipients with a functioning graft for more than 5 years.
    Aziz F, Jung-Hynes B, Parajuli S, Redfield RR, Astor BC, Mandelbrot D, Hidalgo L, Djamali A.
    Clin Nephrol; 2020 Nov 25; 94(5):245-251. PubMed ID: 32870149
    [Abstract] [Full Text] [Related]

  • 19. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.
    Reinsmoen NL, Lai CH, Mirocha J, Cao K, Ong G, Naim M, Wang Q, Haas M, Rafiei M, Czer L, Patel J, Kobashigawa J.
    Transplantation; 2014 Mar 15; 97(5):595-601. PubMed ID: 24162250
    [Abstract] [Full Text] [Related]

  • 20. The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients.
    Urban M, Slavcev A, Gazdic T, Ivak P, Besik J, Netuka I.
    Interact Cardiovasc Thorac Surg; 2016 Mar 15; 22(3):292-7. PubMed ID: 26675563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.